The high incidence of, human immunodeficiency virus (HIV), Chagas, dengue and influenza H1N1, as well as the unavailability of adequate treatments for these infectious diseases spell opportunities for pharmaceutical companies across Latin America to develop new, improved diagnosis and treatment methods.
New analysis from Frost & Sullivan (lifesciences.frost.com), A Product and Pipeline Analysis of the Latin American HIV, Chagas, Dengue, and Influenza H1N1 Therapeutics Markets, finds that Chagas ranks the highest in terms of relative prevalence, and the 50 percent efficacy rate of current treatments means that this is a market to be tapped and developed. HIV has the second-highest incidence rate, followed by dengue and influenza H1N1.
"Pharmaceutical companies in Latin America currently offer numerous generic drugs for the treatment of HIV at reduced prices owing to intense competition in the market," stated Frost & Sullivan Healthcare Industry Analyst Lucila Rocca. "Even though these drugs assure a longer and better life for patients, they do not cure the disease, thus leaving considerable room for more effective therapies."
Although there are presently no effective therapies available for the treatment of dengue, Sanofi-Pasteur will introduce a vaccine by 2016, which will prevent serotypes I, III and IV of the virus. As far as treatment of Chagas is concerned, a pro-drug of ravuconazole and posaconazole is expected to obtain regulatory approval in the next five years.
"Pharmaceutical companies should assist governments across Latin America to control the spread of HIV, Chagas, dengue, and influenza H1N1 mostly resulting from poverty and poor housing by educating the population on the prevalence and causes of these conditions," noted Rocca. "They should also collaborate to improve diagnostic methods and the patients’ access to the system in Latin America."
Overall, the outlook for pharmaceutical companies is promising especially in view of the aging population in Latin America. However, it will be important for generic pharmaceutical companies to continue to offer products at lower prices as governments across the region, which already reimburse 100 percent of the cost of medication to patients infected with HIV and influenza H1N1, purchase large amounts of the lowest-priced medication and vaccines in the market.
If you are interested in more information on this research, please send an email to Francesca Valente, Corporate Communications, at francesca.valente[.]frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.
A Product and Pipeline Analysis of the Latin American HIV, Chagas, Dengue, and Influenza H1N1 Therapeutics Markets is part of the Life Sciences Growth Partnership Service program. Frost & Sullivan’s related research services include: Trends, Opportunities, and Challenges for the Latin American Diabetes Therapeutics Market; China’s 2013 Life Sciences Industry Outlook and Regulatory Review; Competitive Analysis of the Global Opioid Therapeutics Market. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact Us: Start the discussion | Join Us: Join our community | Subscribe: Newsletter on "the next big thing"| Register: Gain access to visionary innovation
A Product and Pipeline Analysis of the Latin American HIV, Chagas, Dengue, and Influenza H1N1 Therapeutics Markets / ND3B-52